Skip to main content
SpringerLink
Log in

Antidepressants are the main options for the long-term pharmacological treatment of generalized anxiety disorder

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Katzmann MA. Current considerations in the treatment of generalized anxiety disorder. CNS Drugs 2009; 23(2): 103–20

    Article  Google Scholar 

  2. Keeton CP, Kolos AC, Walkup JT. Pediatric generalized anxiety disorder: epidemiology, diagnosis and management. Pediatr Drugs 2009; 11(3): 171–83

    Article  Google Scholar 

  3. Canadian Psychiatric Association. Management of anxiety disorders. Can J Psychiatry 2006; 51Suppl. 2: 1–93S

    Google Scholar 

  4. Dhillon S, Scott LJ, Plosker GL. Escitalopram: a review of its use in the management of anxiety disorder. CNS Drugs 2006; 20(9): 763–90

    Article  PubMed  CAS  Google Scholar 

  5. Rickels K, Rynn M, Iyengar M, et al. Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. J Clin Psychiatry 2006; 67(1): 41–7

    Article  PubMed  CAS  Google Scholar 

  6. Brawman-Mintzer O, Knapp RG, Rynn M, et al. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006 Jun; 67(6): 874–81

    Article  PubMed  CAS  Google Scholar 

  7. Allgulander C, Dahl AA, Austin C, et al. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 2004; 161(9): 1642–9

    Article  PubMed  Google Scholar 

  8. Ball SG, Kuhn A, Wall D, et al. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry 2005; 66(1): 94–9

    Article  PubMed  CAS  Google Scholar 

  9. Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 2000 Jun 21; 283(23): 3082–8

    Article  PubMed  CAS  Google Scholar 

  10. Nimatoudis I, Zissis NP, Kogeorgos J, et al. Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder: a double-blind, randomized, placebo controlled study. Int Clin Psychopharmacol 2004; 19(6): 331–6

    Article  PubMed  CAS  Google Scholar 

  11. Lenox-Smith AJ, Reynolds A. A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. Br J Gen Pract 2003; 53(495): 772–7

    PubMed  Google Scholar 

  12. Rynn MA, Riddle MA, Yeung PP, et al. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Am J Psychiatry 2007; 164(2): 290–300

    Article  PubMed  Google Scholar 

  13. Carter NJ, McCormack PL. Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs 2009; 23(6): 523–41

    Article  PubMed  CAS  Google Scholar 

  14. Hartford J, Kornstein S, Liebowitz M, et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 2007; 22(3): 167–74

    Article  PubMed  Google Scholar 

  15. Chessick CA, Allen MH, Thase M, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev 2006; (3): CD006115

  16. Roberts R, Rodriguez W, Murphy D, et al. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA 2003; 290(7): 905–11

    Article  PubMed  Google Scholar 

  17. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50(11): 884–95

    Article  PubMed  CAS  Google Scholar 

  18. Bernstein GA, Borchardt CM, Perwien AR, et al. Imipramine plus cognitive-behavioral therapy in the treatment of school refusal. J Am Acad Child Adolesc Psychiatry 2000; 39(3): 276–83

    Article  PubMed  CAS  Google Scholar 

  19. Klein RG, Koplewicz HS, Kanner A. Imipramine treatment of children with separation anxiety disorder. J Am Acad Child Adolesc Psychiatry 1992; 31(1): 21–8

    Article  PubMed  CAS  Google Scholar 

  20. Bernstein GA, Borchardt CM, Perwien AR. Anxiety disorders in children and adolescents: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1996; 35(9): 1110–9

    Article  PubMed  CAS  Google Scholar 

  21. Bernstein GA, Hektner JM, Borchardt CM, et al. Treatment of school refusal: one-year follow-up. J Am Acad Child Adolesc Psychiatry 2001; 40(2): 206–13

    Article  PubMed  CAS  Google Scholar 

  22. Frampton JE, Foster RH. Pregabalin: in the treatment of generalised anxiety disorder. CNS Drugs 2006; 20(8): 685–93

    Article  PubMed  CAS  Google Scholar 

  23. Pollack MH, Simon NM, Zalta AK, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry 2006 Feb 1; 59(3): 211–5

    Article  PubMed  CAS  Google Scholar 

  24. Katzman MA, Vermani M, Jacobs L, et al. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord 2008 Dec; 22(8): 1480–6

    Article  PubMed  CAS  Google Scholar 

  25. Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 2005 Oct; 66(10): 1321–5

    Article  PubMed  CAS  Google Scholar 

  26. Brawman-Mintzer O, Nietert PJ, Rynn M, et al. Quetiapine monotherapy in patients with GAD [abstract no. NR634]. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20–35; Toronto (ON)

  27. Snyderman SH, Rynn MA, Rickels K. Open-label pilot study of ziprasidone for refractory generalized anxiety disorder. J Clin Psychopharmacol 2005 Oct; 25(5): 497–9

    Article  PubMed  Google Scholar 

  28. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 2008; 359(26): 2753–66

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Antidepressants are the main options for the long-term pharmacological treatment of generalized anxiety disorder. Drugs Ther. Perspect 26, 12–15 (2010). https://doi.org/10.2165/11203530-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11203530-000000000-00000

Search

Navigation